FDA’s Biosimilar Guidances Win Praise For High Hurdles, Flexibility
Executive Summary
Merck Bioventures and Hospira execs say the draft guidances are consistent with their approach to biosimilars development. One attorney says FDA’s broad and flexible approach will require the agency to be careful to ensure a level playing field for sponsors.